You are here: Industry Insights > Dr Reddy

News List

Dr Reddy’s Laboratories completes acquisition of Wockhardt’s select business divisions expresspharma
June 11, 2020
The acquired divisions comprise a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, VMS, dermatology, gastroenterology, pain and vaccines.
Dr Reddy’s recalls its heart burn medicine in the US expresspharma
May 11, 2020
The move comes after US FDA found quality issues like ‘discolouration’ and presence of brown pellets in the company’s 40 mg Esomeprazole Magnesium delayed-release capsules.
Dr Reddy’s gets EIR from USFDA for Srikakulam plant expresspharma
May 08, 2020
All facilities under warning letter are now determined as ‘voluntary action indicated’.
Dr Reddy’s launches generic hemophilia injection in US expresspharma
May 06, 2020
The company has launched desmopressin acetate injection USP, 4 mcg/mL single-dose ampules in the US market, Dr Reddy”s Laboratories said in a filing to the BSE.
Dr Reddy’s Laboratories announces the launch of Invista (dasatinib) in India expresspharma
April 14, 2020
It is indicated for the treatment of chronic accelerated or myeloid or lymphoid blast phase and newly diagnosed in chronic phase adult patients with Chronic Myeloid Leukemia (CML) in India.
Dr Reddy’s recalls four lots of Phytonadione injectable emulsion in US europeanpharmaceuticalreview
April 06, 2020
The FDA has announced that Dr Reddy’s is recalling Phytonadione injectable emulsion because of complaints due to ampules breaking and shattering.
Dr Reddy’s launches generic opioid antagonist injection in US expresspharma
March 23, 2020
The product is a generic version of ADAPT Pharma Operations's Narcan injection.
Dr Reddy’s launches generic Ziprasidone Mesylate for injection in US expresspharma
March 20, 2020
Dr Reddy’s Laboratories said it has launched in the US generic Ziprasidone Mesylate for injection used for treatment of acute agitation in schizophrenic patients.
Dr Reddy’s launches generic oral anti-epileptic drug in US expresspharma
August 21, 2019
Drug firm Dr Reddy’s Laboratories said it has launched generic anti-epileptic Vigabatrin powder for oral solution in the US market. The product is a generic version of Lundbeck’s Sabril powder for oral solution, Dr Reddy’s said in a filing to the BSE.
US FDA completes audit of Dr Reddy’s Louisiana-based facility expresspharma
August 12, 2019
Dr Reddy’s Laboratories announced the US health regulator has completed audit of its Louisiana-based formulations manufacturing facility, following which no form 483 was issued.

Previous page 1 2 3 4 5 Next page